EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma

Biomaterials

Volumn 33, Issue 1, 2012, Pages 270-282

  Gao, Jie ^a,b   Yu, Yongsheng ^a   Zhang, Yingying ^a   Song, Jinjing ^a   Chen, Huaiwen ^a,b   Li, Wei ^a,b   Qian, Weizhu ^a,b   Deng, Li ^a   Kou, Geng ^a,b   Chen, Jianming ^a   Guo, Yajun ^a,b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b National Engineering Research Center for Antibody Medicine   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Antibody; EGFR; HCC; Immunoliposomes; SiRNA delivery

Indexed keywords

ANTI-EGFR; ANTIBODY CONJUGATION; BREAST CANCER; EGFR; EPIDERMAL GROWTH FACTOR RECEPTORS; GENE SILENCING; HCC; HEPATOCELLULAR CARCINOMA; IMMUNOLIPOSOMES; IN-VIVO; INTRAVENOUS INJECTIONS; LUCIFERASE EXPRESSION; ORTHOTOPIC; PEGYLATION; SIRNA DELIVERY; SMALL INTERFERING RNA; TISSUE DISTRIBUTIONS;

ANTIBODIES; CONFOCAL MICROSCOPY; GENETIC ENGINEERING; LIPOSOMES; MAMMALS; PHOSPHOLIPIDS; RNA; TISSUE;

GENE THERAPY;

EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; LUCIFERASE; POLYCATION; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE MODEL; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE SILENCING; HUMANS; LIPOSOMES; LIVER NEOPLASMS; MALE; MICE; POLYETHYLENE GLYCOLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING;

MUS;

EID: 82855165061     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.09.035     Document Type: Article

References (33)

1. Michielsen P.P., Francque S.M., van Dongen J.L. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol 2005, 3:27.
2. McGlynn K.A., Tarone R.E., El-Serag H.B. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006, 15:1198-1203.
3. Sangro B., Prieto J. Gene therapy for liver cancer: clinical experience and future prospects. Curr Opin Mol Ther 2010, 12:561-569.
4. Shi J., Zheng D. An update on gene therapy in China. Curr Opin Mol Ther 2009, 11:547-553.
5. Morille M., Passirani C., Vonarbourg A., Clavreul A., Benoit J.P. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 2008, 29:3477-3496.
6. Xu X.R., Huang J., Xu Z.G., Qian B.Z., Zhu Z.D., Yan Q., et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 2001, 98:15089-15094.
7. Sapra P., Tyagi P., Allen T.M. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2005, 2:369-381.
8. Moreira J.N., Santos A., Moura V., Pedroso de Lima M.C., Simões S. Non-viral lipid-based nanoparticles for targeted cancer systemic gene silencing. J Nanosci Nanotechnol 2008, 8:2184-2204.
9. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007, 6:443-453.
10. Baker M. RNA interference: homing in on delivery. Nature 2010, 464:1225-1228.
11. Tseng Y.C., Mozumdar S., Huang L. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev 2009, 61:721-731.
12. Zimmermann T.S., Lee A.C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., et al. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441:111-114.
13. Li S.D., Chono S., Huang L. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release 2008, 126:77-84.
14. Li S.D., Chen Y.C., Hackett M.J., Huang L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 2008, 16:163-169.
15. Gao J., Liu W., Xia Y., Li W., Sun J., Chen H., et al. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 2011, 32:3459-3470.
16. Giannelli G., Sgarra C., Porcelli L., Azzariti A., Antonaci S., Paradiso A. EGFR and VEGFR as potential target for biological therapies in HCC cells. Cancer Lett 2008, 262:257-264.
17. Dominska M., Dykxhoorn D.M. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 2010, 123:1183-1189.
18. Gao J., Sun J., Li H., Liu W., Zhang Y., Li B., et al. Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing. Biomaterials 2010, 31:2655-2664.
19. Liu Y., Li K., Liu B., Feng S.S. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials 2010, 31:9145-9155.
20. Gao J., Kou G., Wang H., Chen H., Li B., Lu Y., et al. PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity. Breast Cancer Res Treat 2009, 115:29-41.
21. Katas H., Alpar H.O. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release 2006, 115:216-225.
22. Chiu Y.L., Rana T.M. RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell 2002, 10:549-561.
23. Li M., Qian H., Ichim T.E., Ge W.W., Popov I.A., Rycerz K., et al. Induction of RNA interference in dendritic cells. Immunol Res 2004, 30:215-230.
24. Chang Y.W., Bean R.R., Jakobi R. Targeting RhoA/Rho kinase and p21-activated kinase signaling to prevent cancer development and progression. Recent Pat Anticancer Drug Discov 2009, 4:110-124.
25. Yin C., Lin Y., Zhang X., Chen Y.X., Zeng X., Yue H.Y., et al. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4α gene. Hepatology 2008, 48:1528-1539.
26. Kirpotin D., Park J.W., Hong K., Zalipsky S., Li W.L., Carter P., et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997, 36:66-75.
27. Zhang Y., Li H., Sun J., Gao J., Liu W., Li B., et al. DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery. Int J Pharm 2010, 390:198-207.
28. Garbuzenko O., Barenholz Y., Priev A. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids 2005, 135:117-129.
29. Li S.D., Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta 2009, 1788:2259-2266.
30. Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002, 54:631-651.
31. Gao J., Kou G., Chen H., Wang H., Li B., Lu Y., et al. Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab') fragments. Mol Cancer Ther 2008, 7:3399-3407.
32. Visaria R.K., Griffin R.J., Williams B.W., Ebbini E.S., Paciotti G.F., Song C.W., et al. Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor alpha delivery. Mol Cancer Ther 2006, 5:1014-1020.
33. Gao J., Feng S.S., Guo Y. Antibody engineering promotes nanomedicine for cancer treatment. Nanomedicine (Lond) 2010, 5:1141-1145.